sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_7 ;
    pav:version "1.4" .
  sub:_6 prov:value "we examined the requirement for PKCs in the PMA-induced activation of ERKs by using different PKC inhibitors. Treatment with GF109203X resulted in a total inhibition of ERKs activation, whereas rottlerin had no effect (Figure 8). Because rottlerin is unable to block the activation of ERKs by PMA, PKC-d is not implicated in this process. Given that atypical PKCs were not activated by PMA on the XG-6 cells, these results suggest that PKC-z was not involved...Finally, because XG-6 cells express PKC-nu and PKC-d as novel PKC isoforms, we can assume that the novel PKC, namely PCK-nu, is involved in the activation of ERKs by PMA." ;
    prov:wasQuotedFrom pubmed:11485567 .
  sub:_7 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:11485567 ;
    prov:wasDerivedFrom beldoc: , sub:_6 .
}